In breast cancer, high dose estrogen therapy (5–100 μM) on ER positive breast cancer cells leads to inhibition of tumor proliferation and increases the percentage of S-, G2- and M-phase, by decreasing the percentage of G0 and G1 cells [31]. Here, ESR1 is linked to breast carcinoma.